Table 2.
Overview of force measurements in NF, ICM and DCM cardiomyocytes before and after PP2A incubation
| Fmax | Fpas | pCa50 | nH | Max ktr | |
|---|---|---|---|---|---|
| Non-Failing (6 hearts, 14 myocytes) | |||||
| Before PP2A | 19.2 ± 2.5 | 1.8 ± 0.2 | 5.43 ± 0.02 | 5.1 ± 0.4 | 0.67 ± 0.06 |
| After PP2A | 19.0 ± 2.5 | 2.0 ± 0.2 | 5.48 ± 0.01** | 4.9 ± 0.2 | 0.70 ± 0.03 |
| ICM (6 hearts, 14 myocytes) | |||||
| Before PP2A | 19.3 ± 3.0 | 2.1 ± 0.2 | 5.53 ± 0.03# | 4.3 ± 0.3 | 0.65 ± 0.06 |
| After PP2A | 19.4 ± 2.6 | 2.1 ± 0.1 | 5.54 ± 0.03 | 4.2 ± 0.3 | 0.60 ± 0.03 |
| DCM (6 hearts, 13 myocytes) | |||||
| Before PP2A | 19.6 ± 2.3 | 3.2 ± 0.6 | 5.50 ± 0.03 | 4.4 ± 0.3 | 0.60 ± 0.06 |
| After PP2A | 19.4 ± 2.0 | 3.3 ± 0.5 | 5.51 ± 0.03 | 4.4 ± 0.1 | 0.67 ± 0.04 |
F max maximal force in kN/m2, F pas passive force in kN/m2, pCa 50 and nH midpoint and steepness of the force-pCa curves, respectively, Max k tr rate of tension redevelopment (s−1) at saturating calcium concentration (pCa 4.5)
** P < 0.01 before vs. after PP2A treatment (Repeated measures Two-Way ANOVA, n = 6)
# P < 0.05 vs. NF (Two-Way ANOVA (Source of Variation: patient) NS, One-way ANOVA (Ca2+ sensitivity NF, ICM, DCM before PP2A) P = 0.06, Bonferroni’s Multiple comparison test NF vs ICM P < 0.05, n = 6)